The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Drake Peter F since 2007.
The trader's CIK number is 1267854.
At the time of the last reporting, Drake Peter F was the Director of Navidea Biopharmaceuticals, Inc.. (stock ticker symbol NAVB).
Also see all insider trading activities at Navidea Biopharmaceuticals, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2011 | NEOP | 10,000 | $30,780 | 0 | $0 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2008 | RODM | 50,000 | $113,250 | 0 | $0 | 0 | $0 |
| 2007 | RODM | 16,100 | $65,800 | 0 | $0 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2007 | COR | 50,000 | $24,750 | 0 | $0 | 0 | $0 |
1. Navidea Biopharmaceuticals, Inc. (NEOP)
2. Entrust Financial Services Inc (RODM)
3. Respirerx Pharmaceuticals Inc. (COR)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2011-09-15 | NEOP | Buy | 10,000 | 3.08 | 30,780 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2008-08-15 | RODM | Buy | 50,000 | 2.27 | 113,250 |
| 2007-12-04 | RODM | Buy | 16,100 | 4.09 | 65,800 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2007-11-14 | COR | Buy | 50,000 | .49 | 24,750 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Drake Peter F (Director of Navidea Biopharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.